My laboratory has been engaged in translational research in the field of genitourinary malignancies for the past 20 years. After my clinical research training and establishing a kidney cancer research program at Johns Hopkins, I took the leadership of the Genitourinary Program at Roswell Park and then led the Experimental and Developmental Therapeutic Program at the Simon Comprehensive Cancer Center at Indiana University.
I moved recently to the University at Buffalo to build a new cancer research program. Our laboratory and clinical research interests have focused on drug development for genitourinary malignancies. In particular, we have been studying the therapeutic role of histone deacetylase inhibitors in modulating tumor differentiation, angiogenesis and immune responses. We have developed and tested several rational combination strategies of HDAC inhibitors with VEGF and mTOR inhibitors in preclinical models and translated them into clinical trials for bladder, renal cell and prostate carcinoma patients. Moreover, we have shown the synergy between HDAC inhibition and immune therapies and we are conducting clinical trials to test this hypothesis. More recently, we have been testing the role of dietary protein restriction in modulating the immune response. For this proposal I will provide my expertise in tumor biology and patient-derived xenograft models.
This UBMD physician is also a member of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, teaching the next generation of doctors and researching to advance care in WNY and beyond. Learn more about this physician's research and teaching activities, as well as view credentials, publications, professional involvement and more below.